Jennison Associates LLC Buys Shares of 127,907 Abivax SA Sponsored ADR $ABVX

Key Points

• Jennison Associates LLC bought a new stake of 127,907 shares of Abivax (≈$17.25M) in Q4, leaving it with about 0.16% ownership; overall, hedge funds and other institutions own roughly 47.91% of the company.
• Abivax shares opened at $117.61, have a market cap of about $9.33 billion and a negative trailing PE (EPS was -$1.20 last quarter with revenue of $0.52M), and the stock's 1‑year range is $5.59–$148.83.
• Wall Street sentiment is broadly positive with an average rating of Moderate Buy and an average target of $137.15; notable actions include Morgan Stanley raising its target to $145 and giving an "overweight" rating.

Jennison Associates LLC bought a new stake in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 127,907 shares of the company's stock, valued at approximately $17,249,000. Jennison Associates LLC owned about 0.16% of Abivax at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. EverSource Wealth Advisors LLC increased its holdings in Abivax by 4,612.5% during the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company's stock valued at $32,000 after buying an additional 369 shares during the last quarter. First Horizon Corp purchased a new stake in Abivax during the third quarter valued at approximately $36,000. WPG Advisers LLC increased its holdings in Abivax by 125.9% during the fourth quarter. WPG Advisers LLC now owns 454 shares of the company's stock valued at $61,000 after buying an additional 253 shares during the last quarter. Union Bancaire Privee UBP SA purchased a new stake in Abivax during the fourth quarter valued at approximately $67,000. Finally, Hantz Financial Services Inc. purchased a new stake in Abivax during the third quarter valued at approximately $52,000. 47.91% of the stock is owned by hedge funds and other institutional investors.

Abivax Price Performance

Shares of NASDAQ ABVX opened at $117.61 on Friday. The firm has a fifty day moving average price of $117.02 and a 200-day moving average price of $116.44. The stock has a market cap of $9.33 billion, a PE ratio of -21.90 and a beta of 0.84. Abivax SA Sponsored ADR has a 1 year low of $5.59 and a 1 year high of $148.83.

Abivax (NASDAQ:ABVX - Get Free Report) last announced its quarterly earnings data on Saturday, February 14th. The company reported ($1.20) earnings per share (EPS) for the quarter. The firm had revenue of $0.52 million for the quarter. On average, research analysts expect that Abivax SA Sponsored ADR will post -3.84 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Morgan Stanley upped their target price on shares of Abivax from $101.00 to $145.00 and gave the company an "overweight" rating in a report on Friday, January 9th. Oppenheimer set a $131.00 target price on shares of Abivax in a report on Thursday, January 8th. Wall Street Zen cut shares of Abivax from a "hold" rating to a "sell" rating in a report on Sunday, April 26th. Wedbush began coverage on shares of Abivax in a report on Tuesday, February 24th. They set an "outperform" rating and a $110.00 target price for the company. Finally, Oddo Bhf reissued an "outperform" rating on shares of Abivax in a research note on Thursday, April 9th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Abivax has an average rating of "Moderate Buy" and an average target price of $137.15.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.